Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity Abstract #2060

Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Aim(s): The purpose of this study is to assess the clinical, radiological and biochemical response, as well as the safety of PRRT.
Materials and methods: Thirty five (35) patients with histologically confirmed metastatic or unresectable NET were retrospectively studied. Overall response (OR) was recorded at 6 months and 2 years post treatment, incorporating both partial response (PR) and stable disease (SD). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2242 Diagnostic Utility of Ki-67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms
Introduction: Functional imaging with FDG-PET and somatostatin receptors scintigraphy (SRS), play a key role in the diagnosis, treatment and follow-up of patients with neuroendocrine neoplasms (NENs). The proliferative index, ki67, is a reliable pathological marker for grading.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Krystallenia Alexandraki
Keywords: SRS, PET-FDG, ki-67, NENs
#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms
Introduction: A
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD, PhD Miroslaw L Nowicki
#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN
Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Agnieszka Kolasińska-Ćwikła
Keywords: NENs, PRRT, Hindgut, CUP
#2191 Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms
Introduction: Endocrine paraneoplastic syndromes (ePNS) result from production of bioactive substances from tumours not related to their expected tissue of origin. Neuroendocrine neoplasms (NENs) have been associated with ectopic secretion of several hormones, but the prevalence of ePNS has only been described in a small number of studies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Eleftherios Chatzellis
#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Franziska Briest